flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 Effects of Once-Weekly on Disease by KDIGO Risk Category in the SUSTAIN 6 FLOW- the Visual Abstract —
Description
One such development is the utilization of semaglutide designed for the management of type 2 diabetes
Like you were saying, the drug markets themselves weren't that huge back in this era
pmid:40800673 35
-1Glucagon-like peptide-1 receptor, GLP-1RGGLP-1RcAMPcAMPcAMP response element, CRE1GLP-1R [1] 1
With the same dosage and price, it can maintain up to 20 times longer-lasting effects (similar to the difference between an IV drip and a single injection)
